CR20230185A - Compuestos y su uso en el tratamiento del cáncer - Google Patents
Compuestos y su uso en el tratamiento del cáncerInfo
- Publication number
- CR20230185A CR20230185A CR20230185A CR20230185A CR20230185A CR 20230185 A CR20230185 A CR 20230185A CR 20230185 A CR20230185 A CR 20230185A CR 20230185 A CR20230185 A CR 20230185A CR 20230185 A CR20230185 A CR 20230185A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- treating cancer
- relates
- treatment
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063085384P | 2020-09-30 | 2020-09-30 | |
| PCT/EP2021/076752 WO2022069520A1 (en) | 2020-09-30 | 2021-09-29 | Compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230185A true CR20230185A (es) | 2023-06-27 |
Family
ID=78085628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230185A CR20230185A (es) | 2020-09-30 | 2021-09-29 | Compuestos y su uso en el tratamiento del cáncer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230374007A1 (https=) |
| EP (1) | EP4221756A1 (https=) |
| JP (1) | JP2023543299A (https=) |
| KR (1) | KR20230079408A (https=) |
| CN (1) | CN116249554A (https=) |
| AU (2) | AU2021353968B2 (https=) |
| BR (1) | BR112023005708A2 (https=) |
| CA (1) | CA3195695A1 (https=) |
| CL (1) | CL2023000881A1 (https=) |
| CO (1) | CO2023005188A2 (https=) |
| CR (1) | CR20230185A (https=) |
| DO (1) | DOP2023000062A (https=) |
| EC (1) | ECSP23030959A (https=) |
| IL (1) | IL301626A (https=) |
| MX (1) | MX2023003564A (https=) |
| PE (1) | PE20230782A1 (https=) |
| WO (1) | WO2022069520A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115141179B (zh) * | 2021-03-31 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用 |
| CN119301111A (zh) | 2022-03-24 | 2025-01-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物 |
| USD1018676S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| USD1018746S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| USD1020957S1 (en) * | 2022-04-15 | 2024-04-02 | Puttshack LTD | Miniature golf hole |
| USD1018747S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| CN119855812A (zh) * | 2022-09-14 | 2025-04-18 | 海南先声再明医药股份有限公司 | 多并环类化合物及其用途 |
| US20240374588A1 (en) | 2023-04-07 | 2024-11-14 | Astrazeneca Ab | Irak4 protacs |
| TW202515566A (zh) | 2023-06-14 | 2025-04-16 | 瑞典商阿斯特捷利康公司 | Ｓｍａｒｃａ２降解劑及其用途 |
| MX2025015084A (es) * | 2023-06-14 | 2026-02-03 | Astrazeneca Ab | Degradadores de smarca2 y usos de estos |
| WO2025036489A1 (zh) * | 2023-08-17 | 2025-02-20 | 海思科医药集团股份有限公司 | 一种氰基芳香环衍生物及其在医药上的应用 |
| IL326555A (en) | 2023-09-22 | 2026-04-01 | Glaxosmithkline Ip Dev Ltd | Androgen receptor protax |
| CN117430605A (zh) * | 2023-10-26 | 2024-01-23 | 广西天铭药业有限公司 | 一种kras g12c抑制剂amg-510中间体的合成方法 |
| US20250177539A1 (en) * | 2023-12-01 | 2025-06-05 | Astrazeneca Ab | Er degraders and uses thereof |
| WO2025125575A1 (en) | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0422263D0 (en) | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
| PH12012502079A1 (en) | 2010-04-16 | 2013-02-11 | Ac Immune Sa | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| JP6509838B2 (ja) | 2013-06-26 | 2019-05-08 | アッヴィ・インコーポレイテッド | Ｂｔｋ阻害薬としての一級カルボキサミド類 |
| ES2826443T3 (es) | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| BR112019015484A2 (pt) * | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| WO2019057757A1 (en) * | 2017-09-20 | 2019-03-28 | Astrazeneca Ab | 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER |
| WO2019140387A1 (en) * | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CN120698983A (zh) * | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
-
2021
- 2021-09-29 EP EP21787317.3A patent/EP4221756A1/en active Pending
- 2021-09-29 BR BR112023005708A patent/BR112023005708A2/pt unknown
- 2021-09-29 KR KR1020237014514A patent/KR20230079408A/ko active Pending
- 2021-09-29 IL IL301626A patent/IL301626A/en unknown
- 2021-09-29 CR CR20230185A patent/CR20230185A/es unknown
- 2021-09-29 WO PCT/EP2021/076752 patent/WO2022069520A1/en not_active Ceased
- 2021-09-29 CN CN202180065971.2A patent/CN116249554A/zh active Pending
- 2021-09-29 US US18/247,014 patent/US20230374007A1/en active Pending
- 2021-09-29 CA CA3195695A patent/CA3195695A1/en active Pending
- 2021-09-29 AU AU2021353968A patent/AU2021353968B2/en active Active
- 2021-09-29 MX MX2023003564A patent/MX2023003564A/es unknown
- 2021-09-29 PE PE2023001220A patent/PE20230782A1/es unknown
- 2021-09-29 JP JP2023519522A patent/JP2023543299A/ja active Pending
-
2023
- 2023-03-24 DO DO2023000062A patent/DOP2023000062A/es unknown
- 2023-03-27 CL CL2023000881A patent/CL2023000881A1/es unknown
- 2023-04-24 CO CONC2023/0005188A patent/CO2023005188A2/es unknown
- 2023-04-27 EC ECSENADI202330959A patent/ECSP23030959A/es unknown
-
2025
- 2025-01-09 AU AU2025200137A patent/AU2025200137A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022069520A1 (en) | 2022-04-07 |
| JP2023543299A (ja) | 2023-10-13 |
| US20230374007A1 (en) | 2023-11-23 |
| CL2023000881A1 (es) | 2023-11-17 |
| AU2021353968A9 (en) | 2024-10-03 |
| AU2025200137A1 (en) | 2025-01-30 |
| EP4221756A1 (en) | 2023-08-09 |
| AU2021353968A1 (en) | 2023-06-08 |
| MX2023003564A (es) | 2023-04-04 |
| CO2023005188A2 (es) | 2023-05-19 |
| AU2021353968B2 (en) | 2024-10-10 |
| KR20230079408A (ko) | 2023-06-07 |
| PE20230782A1 (es) | 2023-05-09 |
| DOP2023000062A (es) | 2023-05-31 |
| ECSP23030959A (es) | 2023-05-31 |
| CN116249554A (zh) | 2023-06-09 |
| CA3195695A1 (en) | 2022-04-07 |
| BR112023005708A2 (pt) | 2023-05-02 |
| IL301626A (en) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230185A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| PH12021552362A1 (en) | Estrogen receptor degrading protacs | |
| JOP20220271A1 (ar) | مركبات دايازينو بيريميدين كمثبطات لـ her2 | |
| MX2024006681A (es) | Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer. | |
| MY200810A (en) | Pyrrolidine compounds | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2020013570A (es) | Compuestos de purinona y su uso en el tratamiento del cancer. | |
| MX2023003627A (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer. | |
| MX2024014117A (es) | Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas | |
| WO2006067445A3 (en) | Csf-1r kinase inhibitors | |
| MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| CA3242612A1 (en) | Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions | |
| MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
| MX2024005766A (es) | Compuesto de imidazo[4,5-b]piridina cristalina, composiciones farmacéuticas y su uso en el tratamiento de condiciones médicas. | |
| MX2023014131A (es) | Derivado de 7-nitro-8-hidroxiquinolina, metodo de preparacion y uso medico del mismo. | |
| JOP20190209A1 (ar) | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان | |
| MX2023007150A (es) | Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos. | |
| MX2023014784A (es) | Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos. | |
| WO2022204344A3 (en) | Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents | |
| EP4620940A3 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| WO2022048618A8 (en) | Methods to treat inflammatory bowel disease | |
| MX2022015005A (es) | Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1. |